DNAH8 and cardiomyopathy: Myosin ATPase inhibitors are being developed for the treatment of cardiomyopathy caused by similar mutations of cardiac myosin heavy chain genes (Green et al, 2016); therefore, we sought to determine whether drugs that directly inhibit function of myosin (Kovács et al, 2004) could reduce the adverse phenotypic effects of the smyhc1R673H allele.